U.S. Markets closed

Cytosorbents Corporation (CTSO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.350.00 (0.00%)
At close: 4:00PM EDT
People also watch
AEMDELTPADXSONCSTTNP

Cytosorbents Corporation

7 Deer Park Drive
Suite K
Monmouth Junction, NJ 08852
United States
732-329-8885
http://www.cytosorbents.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees70

Key Executives

NameTitlePayExercisedAge
Dr. Phillip P. Chan M.D., Ph.D.Chief Exec. Officer, Pres and Director350kN/A47
Ms. Kathleen P. Bloch MBA, CPAChief Financial Officer and Sec.255kN/A62
Mr. Vincent J. Capponi MSChief Operating Officer291kN/A59
Dr. Robert H. Bartlett M.D.Chief Medical Officer and Member of Cardiac Surgery Advisory Board54kN/A78
Dr. Christian Steiner M.D.VP of Sales & MarketingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, CytoSorbents Corporation is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.

Corporate Governance

Cytosorbents Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.